Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
A research team has established a CRISPR/Cas9 gene-editing system for Chrysanthemum morifolium, targeting the CmPDS gene to explore gene functions and enhance breeding. By combining transient and ...
In the present study, we investigated whether electroporation could be used for one-step multiplex CRISPR/Cas9-based genome editing, targeting IL2RG and GHR in porcine embryos. First, we evaluated and ...
A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing. The results demonstrate how ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at their genetic source.
Immunotherapeutic strategies have made huge strides in cancer treatment for many solid tumors over the past decade. But the promising results have failed to make a large change in the treatment of ...
An appeals court has opened another chapter in the long-running CRISPR patent saga. Three years after a patent body ruled in favor of the teams behind Editas Medicine’s intellectual property, an ...
License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities DUBLIN and JUPITER, Fla., Nov. 10, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS') ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback